MedTrace Logo

Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.

NCT05703802 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-06-04

No results posted yet for this study

Summary

Procalcitonin is a protein consisting of 116 amino-acids which can rapidly rise under inflammatory conditions and sepsis. More than 20 years ago it has been shown that dipeptidylpeptidase-4 (DPP-4) cleaves procalcitonin from the n-terminus, resulting in a truncated procalcitonin-variant which consists of 114 aminoacids. Within their workgroup the investigators found that the truncated procalcitonin-variant had deleterious effects on vascular integrity during sepsis in mice. However, it is unknown if this applies also in humans. By using an ELISA-assay the investigators want to examine the ratio between native and truncated human procalcitonin during diseases accompanied with hyperprocalcitoninemia and correlate the results with clinical data.

Conditions

  • Sepsis
  • Pre-Eclampsia
  • Granulomatosis With Polyangiitis
  • Microscopic Polyangiitis
  • Adiposity
  • SIRS
  • Procalcitonin

Interventions

DIAGNOSTIC_TEST

Procalcitonin-variants ELISA-Assay

Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.

Sponsors & Collaborators

  • University Hospital Muenster

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-11-01
Completion
2022-11-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05703802 on ClinicalTrials.gov